Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | NPC1 | O15118 | 4/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480252 | 1.00 | ALDH1A1 (0.81) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1578826 | 0.98 | ALDH1A1 (0.78) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3077817 | 0.94 | SMN1; SMN2 (0.72) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5653225 | 0.93 | ALDH1A1 (0.77) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8845496 | 0.93 | ALDH1A1 (0.77) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8845129 | 0.91 | KMT2A (0.73) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL11882343 | 0.90 | MGLL (0.72) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5650832 | 0.90 | KMT2A (1.00) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5646504 | 0.85 | KMT2A (0.70) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL27780514 | 0.85 | MGLL (0.66) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108617386-B | Ecological cultivation mode for leisure and sightseeing of persimmon orchard in mountainous region | 湖北省农业科学院果树茶叶研究所 | 2020-06-16 | — | — | CN | claimed |
| CN-102918027-A | Modulators of the gpr119 receptor and the treatment of disorders related thereto | ARENA PHARM INC | 2013-02-06 | — | — | CN | claimed |
| CN-1436175-A | Cyclic lactams as inhibitors of A beta-protein production | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-08-13 | — | — | CN | claimed |
| EP-0635004-B1 | 4-DIPHENYLMETHYL PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MERRELL PHARMA INC (US) | 2002-07-17 | — | — | EP | claimed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| CN-116848238-A | Macrocyclic complement factor B inhibitors | 阿雷克森制药公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116589467-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116589466-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof | 百济神州有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| CN-116133658-A | Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same | 株式会社 钟根堂 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-4408053-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4408054-A | ANALGESTICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0080104-A2 | 3-(4-Piperidyl)-1,2-benzisoxazoles, process for the preparation thereof, and a pharmaceutical composition comprising the same | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0079564-A1 | 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles, a process for the preparation thereof, a pharmaceutical composition comprising the same, and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-05-25 | — | — | EP | disclosed |
| US-4355037-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1982-10-19 | — | — | US | disclosed |
| US-4234484-A | FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
| US-4149941-A | ELECTROLYTIC ALKOXYLATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | disclosed |
| US-4118500-A | Fungicidal alkoxy mono- and dialkoxy N-substituted cyclic amines | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | ALDH1A1 4088/4885POLB 4764/4885KMT2A 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.